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Objective: To evaluate the usefulness of DNA methods to provide a means to precisely genotypically match 
donor blood units for the antigen-negative type of 35 sickle cell disease patients.
Methods: Red blood cell units were investigated for ABO, D, C, c, E, e, K, Fya, Fyb, Jka, Jkb, S, s, Dia and 
RH variants by performing a molecular array (Human Erythrocyte Antigen BeadChipTM, BioArray Solutions), 
polymerase chain reaction followed by restriction fragment length polymorphism analysis and sequencing of 
patient samples and donor units that had been serologically matched based on the ABO, Rh and K phenotypes 
and the presence of antibodies.
Results: Matches for 21 of 35 sickle cell disease patients presented discrepancies or mismatches for multiple 
antigens between the genotype profile and the antigen profile of their serologically-matched blood units. The 
main discrepancies or mismatches occurred in the RH, FY, JK and MNS systems. Eight Rh alloimmunized 
patients presented RHD and RHCE variants that had not been serologically identified. According to these 
results better matches were found for the patients with genotyped units and the patients benefited as shown by 
better in vivo red blood cell survival.
Conclusion: Molecular matching is superior to serological matching in sickle cell disease patients, decreasing 
the risk of transfusion reactions, especially delayed transfusion reactions to existing alloantibodies and 
preventing alloimmunization.
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Introduction
Red blood cell (RBC) transfusions have played an important role in allowing sickle cell 
disease (SCD) patients to live longer. However, their use is complicated by the high incidence 
of RBC alloimmunization(1-7), making the identification of compatible RBC products difficult, 
and is associated with delayed hemolytic transfusion reactions (DHTRs). For it to be possible to 
transfuse SCD patients effectively, more effective ways to reduce risk of transfusion reactions, 
transfusion-associated hyperhemolysis syndrome and alloimmunization must be found.
Although transfusion services establish protocols to reduce alloimmunization, there is 
still no consensus on the best practical approach even though the obvious goal is to provide 
blood that will survive for the maximum period of time(8-10). Three common approaches used 
to supply RBC products (ABO and D compatible) to SCD patients are (i) to give specific 
antigen-negative RBCs after the patient has made the alloantibody, (ii) to match for C, E, c, e 
and K antigens and (iii) to match for C, E, c, e, K, Fya, Fyb, Jka and Jkb antigens(11-14). 
In recent years, molecular DNA-based genetic methods have greatly improved transfusion 
therapy for SCD patients because they can be used to genotype patients and donors and maintain an 
inventory of DNA-typed units to identify compatible donors. Previous studies have demonstrated 
the relevance of genotyping blood groups to manage multiply transfused SCD patients by allowing 
the determination of the true blood group genotype and by assisting the identification of suspected 
alloantibodies and the selection of antigen-negative RBCs for transfusion(15,16). 
By testing the patient and donors it is possible to provide more extensively matched blood 
for patients thereby preventing additional alloimmunization. A study by Klapper et al.(17) using 
the human erythrocyte antigen (HEA) BeadChipTM DNA analysis and a web-based inventory 
management system to model donor-recipient matching showed that even with a limited donor 
pool, matching for Rh, Kell, Duffy, Kidd and MNS could be achieved at least 50% of the time. 
Herein the use of DNA methods to precisely match donor blood units for the 
antigen-negative genotypes of SCD patients is reported. 
 
Methods
Samples
DNA samples from one hundred and ten donor units from a blood bank inventory 
that had been serologically matched for 35 SCD patients were studied. Selected units were 
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serologically matched for patients based on their ABO, Rh and 
K phenotypes and the presence of antibodies. Antigen-matched 
RBC units were investigated for recipients using blood group 
genotypes of the ABO, D, C, c, E, e, K, Fya, Fyb, Jka, Jkb, S, Lua, 
Dia,  Jsb, Doa and Dob systems. All the patients and donors agreed 
to participate in this study by signing an Institute Review Board 
approved informed consent form. 
 
Data processing
To perform data management, a web-hosted inventory 
management system was designed for this study. An electronic 
link using specific software to compare the blood donor units 
and the patients’ needs was established allowing automatic 
identification of the most compatible blood. 
 
DNA preparation
The genomic DNA was extracted from 200-µL aliquots 
of whole blood by manual spin column separation (QIAmp, 
Qiagen, Valencia, CA), according to the instructions of 
the manufacturer and eluted into 100 µL of buffer. The 
DNA concentration of each sample was calculated by the 
measurement of optical density at 260 and 280 nm and an 8-µL 
aliquot, containing ~10 ng of gDNA, was transferred for the 
polymerase chain reaction (PCR).
 
Human erythrocyte antigen BeadChipTM DNA analysis
The DNA array analysis was performed using RHD 
and RHCE BeadChipTM analysis which uses probes directed 
to polymorphic sites for RHD and RHCE variants and HEA 
BeadChipTM containing probes directed to polymorphic 
sites in the RHCE, FY (including FY-GATA and FY265), DO 
(including HY and JO), CO, DI, SC, GYPA, GYPB (including 
markers permitting the identification of U-negative and 
U-variant types), LU, KEL, JK and LW  genes and one mutation 
associated with hemoglobinopathies (Hb S) (BioArray 
Solutions, Warren, NJ, USA) for all donor and patient samples. 
The HEA BeadChipTM assay was performed in accordance 
with a previously described protocol(16,18,19).
 
Polymerase chain reaction-restriction fragment length 
polymorphism 
PCR followed by restriction fragment length polymorphism 
(RFLP) was used to identify the RHCE*ceBI and RHD*DOL 
variants prevalent in African descendents. Screening of samples 
was carried out by analyzing RHCE*818 and RHCE*1132 in 
standard PCR products generated from genomic DNA using 
RHCE-specific-primers, followed by RFLP using the MwoI and 
Tsp45I restriction enzymes, respectively(20). Genomic DNA was 
amplified using RHD-specific primers flanking exon 4 and exon 
8, with the products being submitted to sequencing to determine 
the presence of the RHD*DOL (nt 509T>C in exon 4) and 
RHD*DOL-2 alleles (nt 509T>C in exon 4 and nt 1132C>G in 
exon 8). PCR products were sequenced in both directions. 
Results
Molecular matching
Of the 35 SCD patients studied, 21 presented discrepancies 
or mismatches for multiple antigens between their extended 
HEA (xHEA) profile and the antigen profiles of their 
serologically-matched blood units. The main discrepancies 
or mismatches occurred in the RH, FY, JK and MNS 
systems. Discrepancies between the previous phenotype and 
genotype-derived phenotype were found in 14 alloimmunized 
chronically transfused patients (Table 1) who were not having 
good in vivo RBC survival and mismatches for multiple antigens 
were found in 17 patients receiving blood units matched for ABO, 
Rh and K. Eight Rh alloimmunized patients presented RHD and 
RHCE variants that had not been serologically identified or that 
had been misinterpreted as autoantibodies. Of these eight patients, 
two had the RHCE*ceAR associated with the RHD*DAR variant, 
two had the RHCE*ceBI associated with the RHD*DOL variant, 
two had RHCE*ce48C,733G and two had RHCE*ce48C,733G, 
1006T, both associated with the RHD*DIIIa variant (Table 2). 
According to these results, better matches were found for the 
patients in the institution’s DNA-typed units, and in the majority 
of cases, the degree of matching was enhanced and the patients 
benefited by receiving transfusions that provided better in vivo 
RBC survival. The transfusion timeline before genotyping was 
about 1 week, and with extended genotyped-matched blood this 
changed to 30 days. These patients were followed up for one year 
and have not developed other antibodies.
Table 1 - Phenotyping and genotyping discrepancies found in the samples of 
14 sickle cell disease patients 
Genotyping Phenotyping
RH system RhC+c- RhC+c+ RhC-c+
RHCE*CC 0 2 1
RHCE*Cc 0 0 3
RhE+e- RhE+e+ RhE-e+
RHCE*EE 0 0 0
RHCE*Ee 1 0 2
Duffy System Fy(a+b-) Fy(a+b+) Fy(a-b+)
FY*A/FY*B (T/T) 0 0 2
Kidd System Jk(a+b-) Jk(a+b+) Jk(a-b+)
JK*A/JK*B 0 0 2
MNS System S+s- S+s+ S-s+
GYPB*Ss 0 0 1
Table 2 - RHD and RHCE variants found in eight sickle 
cell disease patients  
n RHD RHCE
2 RHD*DAR RHCE*ceAR
2 RHD*DOL RHCE*ceBI
2 - RHCE*ce48C, 733G
2 RHD*DIIIa RHCE*ce48C, 733G, 1006T
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extensive DNA-based blood group typing of donors and patients 
has shown to be a cost-effective procedure and now chronically 
SCD patients can be screened for at least the lack of the C, c, E, 
e, K, S, Fya, Jka and Jkb antigens.
The reliable prediction of xHEA phenotypes offers a 
potential alternative to the current serologic methods of donor unit 
screening and transfusion recipient typing. DNA array technology 
can contribute to the management of transfusions in SCD patients 
by facilitating transfusion support with antigen-matched blood. It 
has the potential to replace the routine blood group phenotyping 
with a reduction in costs as well as the workload involved in 
donor and patient antigen typing.
Conclusion
In summary, the implementation of molecular matching 
can decrease the risk of transfusion reactions, especially delayed 
transfusion reactions to existing alloantibodies, and prevents 
alloimmunization. Additionally, the degree of enhanced matching 
was higher than that which occurred by random based matching 
of only the ABO, Rh and K systems. Matching at the DNA level 
may provide an added level of safety and efficacy by reducing 
transfusion requirements, decreasing the risk of transfusion-related 
acute lung injury and potential exposure to infectious diseases.
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